UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Cervical Cancer Elimination -Using Implementation Science to Evaluate Deliver and Cost Introduction of Thermal Ablation

Not Applicable

Recruiting

Conditions: Cervical Cancer

Interventions: Other: Thermal Ablation

First Posted Date: 2022-07-25

Last Posted Date: 2024-08-19

Lead Sponsor: University of Washington

Target Recruit Count: 565

Registration Number: NCT05472311

Locations: 🇰🇪
Phrd-Ccr-Kemri, Thika, Kiambu, Kenya

Effect of Estrogen Treatment on Drug Metabolism and Transport

Phase 4

Recruiting

Conditions: Transgender Persons

Interventions: Drug: Midazolam oral solution
Drug: Digoxin Oral Tablet
Drug: Acetaminophen Oral Tablet
Drug: Midazolam Injectable Solution

First Posted Date: 2022-07-21

Last Posted Date: 2024-07-12

Lead Sponsor: University of Washington

Target Recruit Count: 13

Registration Number: NCT05469204

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Optimal Timing of Computerized Cognitive Training for Older Intensive Care Unit Survivors

Not Applicable

Recruiting

Conditions: Circadian Dysrhythmia
Aging
Critical Illness
Cognitive Impairment
Intensive Care Unit Delirium

Interventions: Behavioral: COG-AM
Behavioral: COG-PM

First Posted Date: 2022-07-20

Last Posted Date: 2024-04-29

Lead Sponsor: University of Washington

Target Recruit Count: 40

Registration Number: NCT05467410

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Enhancing PrEP Outcomes Among Kenyan Adolescent Girls and Young Women With a Novel Pharmacy-based PrEP Delivery Platform

Not Applicable

Recruiting

Conditions: Hiv

Interventions: Behavioral: Nurse-Navigator Enhanced PrEP Support

First Posted Date: 2022-07-20

Last Posted Date: 2024-07-22

Lead Sponsor: University of Washington

Target Recruit Count: 1900

Registration Number: NCT05467306

Locations: 🇰🇪
Kenya Medical Research Institute, Kisumu, Kenya

PrEP for Prevention of HIV Transmission Among People Who Inject Drugs in Nairobi, Kenya

Not Applicable

Conditions: PrEP Uptake
HIV Antibody Positivity

Interventions: Behavioral: Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)

First Posted Date: 2022-07-19

Last Posted Date: 2022-07-22

Lead Sponsor: University of Washington

Target Recruit Count: 256

Registration Number: NCT05465265

Locations: 🇰🇪
Pangani DIC, Ngara DIC, Githurai DIC, Kawangware DIC, Nairobi, Kenya

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma

Interventions: Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Biological: Retifanlimab
Biological: Rituximab and Hyaluronidase Human
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Multigated Acquisition Scan
Other: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Drug: Polatuzumab Vedotin

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-20

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT05455697

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Anatomic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8

Interventions: Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Biological: Sargramostim

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-20

Lead Sponsor: University of Washington

Target Recruit Count: 33

Registration Number: NCT05455658

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Effect of Commute Traffic on Vascular Function

Not Applicable

Completed

Conditions: Cardiovascular Diseases

Interventions: Other: Filtered Air

First Posted Date: 2022-07-12

Last Posted Date: 2022-07-12

Lead Sponsor: University of Washington

Target Recruit Count: 16

Registration Number: NCT05454930

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Colonoscopy Outreach for Rural Communities Aim 2

Not Applicable

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Behavioral: Usual Care Control
Behavioral: Patient Navigation

First Posted Date: 2022-07-12

Last Posted Date: 2024-05-30

Lead Sponsor: University of Washington

Target Recruit Count: 527

Registration Number: NCT05453630

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2

Recruiting

Conditions: Post-Transplant Lymphoproliferative Disorder
Refractory Mantle Cell Lymphoma
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: Loncastuximab Tesirine

First Posted Date: 2022-07-12

Last Posted Date: 2024-10-17

Lead Sponsor: University of Washington

Target Recruit Count: 40

Registration Number: NCT05453396

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy